阴道小细胞神经内分泌癌的新疗法
Novel Treatment of Small-Cell Neuroendocrine of the Vagina.
作者信息
Kostamo Kathryn, Peart Mishka, McKenzie Nathalie, Holloman Conisha, Carlan S J, Ge Li, Maksem John
机构信息
Department of Obstetrics and Gynecology, Orlando Regional Healthcare, Orlando, FL, USA.
Gynecologic Oncology, Florida Hospital Medical Group, Maitland, FL, USA.
出版信息
Case Rep Oncol Med. 2018 Feb 4;2018:9157036. doi: 10.1155/2018/9157036. eCollection 2018.
BACKGROUND
Primary vaginal small-cell neuroendocrine carcinoma is an extremely rare and highly aggressive malignancy. Eighty-five percent of patients die within one year of diagnosis from metastatic disease despite multimodal therapy. Gene expression profiling of tumor tissue may be useful for treatment options for various malignancies.
CASE
A 34-year-old nulliparous woman was diagnosed with primary vaginal small-cell neuroendocrine carcinoma. Twenty weeks after the initial visit, she was diagnosed with recurrence and started on chemoradiation based on the results of gene expression profile of tumor tissue. She died 34 months after the initial visit and had a 14-month progression-free survival (PFS).
CONCLUSION
Gene expression profile of tumor tissue in the management of primary vaginal small-cell neuroendocrine carcinoma may be helpful in extending progression-free survival.
背景
原发性阴道小细胞神经内分泌癌是一种极其罕见且侵袭性很强的恶性肿瘤。尽管采用了多模式治疗，但85%的患者在诊断后一年内死于转移性疾病。肿瘤组织的基因表达谱分析可能有助于为各种恶性肿瘤选择治疗方案。
病例
一名34岁未生育的女性被诊断为原发性阴道小细胞神经内分泌癌。初诊20周后，她被诊断为复发，并根据肿瘤组织基因表达谱的结果开始进行放化疗。她在初诊34个月后死亡，无进展生存期（PFS）为14个月。
结论
肿瘤组织的基因表达谱分析在原发性阴道小细胞神经内分泌癌的治疗中可能有助于延长无进展生存期。
Zotero 插件